India’s premier research organization, the council of Scientific & Industrial Research (CSIR) today announced its partnership with India-based subsidiary of leading global pharmaceutical company Mylan Laboratories Limited.
This partnership is announced to address unmet patient needs amidst the evolving COVID-19 pandemic. Under this partnership, the CSIR’s constituent laboratory Indian Institute of Chemical Technology (CSIR-IICT), and Mylan will collaborate to identify possible therapies for COVID-19.
Director-General of CSIR, Dr. Shehkar C Mande said, “The current collaboration with Mylan is a significant milestone. During the current COVID-19 pandemic, CSIR has prioritized conducting clinical trials of well-proven drugs in partnership with industry towards the development of multiple therapeutic options for COVID-19.”
CSIR & Mylan Announce Partnership to identify Advance Therapeutic Options for Management of COVID 19 and take up clinical trials @PMOIndia @drharshvardhan @PrinSciAdvGoI @shekhar_mande @csiriict @MylanNews @PIB_India pic.twitter.com/xQNuS3CwQY
— CSIR (@CSIR_IND) September 23, 2020
As a part of this collaboration, a series of clinical trials will be performed towards accomplishing new and innovative solutions to manage the COVID-19 pandemic in India. A multiple arm phase 3 study will be conducted in adult patients with mild to moderate symptoms of COVID-19 with the first clinical trials.
Sanjeev Sethi, Mylan’s Chief Operating Officer, said, “Our collaboration with CSIR is a strategic step forward aimed at identifying effective treatments for patients with COVID-19. In addition to bringing forward new indications, this partnership will also help us identify multiple molecules that can be leveraged in therapies for various other infectious diseases in the future.”
.@CSIR_IND & Mylan Laboratories Ltd announce partnership to identify advance therapeutic options for management of #COVID19
A series of clinical trials will be conducted towards new & innovative solutions to manage COVID-19 as part of this collaborationhttps://t.co/5aTNLxvl3m
— PIB India (@PIB_India) September 23, 2020
Ram Vishwakarma, Honorary Advisor to DG-CSIR and former Director CSIR-IIIM (Indian Institute of Integrative Medicine), has been appointed as an adviser to lead this collaboration by the council of Scientific & Industrial Research (CSIR).
Meanwhile, the application for the clinical trials has been submitted to the Drugs Controller General of India (DCGI) for regulatory approval.
Mylan is committed to setting new standards in the healthcare sector and is one of the world’s largest producers of active pharmaceutical ingredients.
The Council of Scientific & Industrial Research (CSIR) is famous for its advanced R&D knowledge base in diverse Science & Technology areas. It is a contemporary and premier R&D organization.
Having a pan-India existence, CSIR has a dynamic network of 38 national laboratories, 39 outreach centers, 3 Innovation Complexes, and 5 units.
CSIR covers a wide spectrum of science and technology – from oceanography, geophysics, chemicals, drugs, genomics, biotechnology, and nanotechnology to mining, aeronautics, instrumentation, environmental engineering, and information technology.
